World Health Organisation (WHO) says more than 124,000 Africans die each year as a result of undiagnosed and untreated hepatitis.
Dr. Matshidiso Moeti, WHO Regional Director for Africa, said this in her message to commemorate World Hepatitis Day, aimed at increasing awareness of the disease under the theme: `Hepatitis can’t wait.
Moeti said the disease inflames the liver and can lead to liver cancer and cirrhosis, calling on all countries to rapidly improve access to services to prevent, diagnose and treat the disease.
Hepatitis is a silent epidemic with more than 90 million people living with the disease in Africa, representing 26 percent of the global total, she noted.
The WHO director added that around 4.5 million African children, less than five years, were infected with chronic hepatitis B, reflecting an enormous 70 per cent of the global burden in that age group.
Moeti said the global target of less than 1 per cent incidence of hepatitis B in children under 5 years has been reached, but the African region was lagging behind at 2.5 per cent.
She said that most of such cases could be prevented by eliminating the Mother-To-Child Transmission (PMTCT) of the disease, during or shortly after birth and in early childhood.
“Key interventions against hepatitis B include vaccination at birth and in early childhood, screening pregnant women, and providing timely treatment.”
She said that countries are been encouraged to integrate the hepatitis B PMTCT in the ante-natal care package together with the HIV and Syphilis PMTCT programme, especially after it was found that only 14 countries in the region were implementing the hepatitis B birth dose vaccine.
“Among people who are infected, nine out of 10 have never been tested, because of limited awareness and access to testing and treatment.
“Even among countries offering hepatitis B birth-dose vaccine, health systems are facing challenges in ensuring pregnant women and mothers are tested and that those who test positive are treated.
“At the same time, there are many promising developments on hepatitis. With the launch of the first global strategy on hepatitis in 2016, along with increased advocacy in recent years, political will is starting to translate into action.
“Hepatitis medicines have also become much more affordable, with prices as low as $60 dollars per patient for a 12-week treatment, she said.
Moeti said that African heads of states had committed to addressing viral hepatitis as a public health threat in the Cairo Declaration in February 2020 and that the Egyptian Initiative planned to provide hepatitis C treatment for one million Africans, with South Sudan, Eritrea and Chad already reaching 50,000 people.
“Apart from them, Rwanda, Uganda, and Benin have established free testing and treatment programmes for hepatitis and 16 other countries are starting pilot projects in that direction.
“To guide action on hepatitis, 28 African countries now have strategic plans in place and at the global level WHO guidelines were launched in 2020 on prevention of mother-to-child transmission of hepatitis B.”
She added that the WHO Regional Office for Africa was developing training materials in order to help countries implement the five hepatitis core interventions and decentralize diagnosis and treatment.
Moeti, therefore, called on all stakeholders in maternal and child health to consider how hepatitis could be integrated into existing initiatives because health systems play a vital role in preventing transmission by making sure blood donations were screened and syringes were used only once and then safely disposed of.
She also called on individuals to seek testing and treatment for hepatitis and to learn more about the disease so as to end the silent epidemic.
